Pelthos Therapeutics Inc.
PTHS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $3 | $0 | $0 |
| G&A Expenses | $6 | $4 | $2 | $1 |
| SG&A Expenses | $6 | $4 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8 | $7 | $2 | $1 |
| Operating Income | -$8 | -$7 | -$2 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$1 | -$0 | $0 |
| Pre-Tax Income | -$8 | -$7 | -$2 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$7 | -$2 | -$1 |
| % Margin | – | – | – | – |
| EPS | -13.54 | -12.8 | -4.26 | -1 |
| % Growth | -5.8% | -200.5% | -326% | – |
| EPS Diluted | -13.54 | -12.8 | -4.26 | -1 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$7 | -$2 | -$1 |
| % Margin | – | – | – | – |